Longitudinal Dynamics of SARS-CoV-2 IgG Antibody Responses after the Two-Dose Regimen of BNT162b2 Vaccination and the Effect of a Third Dose on Healthcare Workers in Japan

• Published in: Vaccines (Basel) 2022-05, Vol.10 (6), p.830
• Main Authors: Sakamoto, Atsuhiko, Yoshimura, Michinobu, Itoh, Ryota, Ozuru, Ryo, Ishii, Kazunari, Sechi, Yusuke, Nabeshima, Shigeki, Hiromatsu, Kenji
• Format: Article
• Language: English
• Subjects: Adverse events; Age; Age factors; antibody response; BNT162b2; Coronaviruses; COVID-19; COVID-19 vaccines; Health care; Humoral immunity; IgG antibody; Immune response (humoral); Immunoglobulin G; Infections; Medical personnel; Monoclonal antibodies; mRNA vaccine; Older people; Proteins; Regression analysis; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Vaccination; Vaccines
• ISSN: 2076-393X; 2076-393X
• DOI: 10.3390/vaccines10060830

Analysis of longitudinal dynamics of humoral immune responses to the BNT162b2 COVID-19 vaccine might provide useful information to predict the effectiveness of BNT162b2 in preventing SARS-CoV-2 infection. Herein, we measure anti-RBD IgG at 1, 3 and 6 months (M) after the second dose of BNT162b2, and at 1 M after a third dose of BNT162b2 vaccination in 431 COVID-19-naïve healthcare workers (HCWs) in Japan. All HCWs mounted high-anti-RBD IgG responses after the two-dose regimen of BNT162b2 vaccinations. Older persons and males presented lower anti-RBD IgG responses than younger adults and females, respectively. The decay in anti-RBD IgG started from 1 M after the second dose of BNT162b2 and anti-RBD IgG titers dropped to nearly one-tenth at 6 M after the second vaccination. Subsequently, the participants received a third dose of BNT162b2 at 8 M after the second dose of BNT162b2 vaccine. Anti-RBD antibody titers 1 M after the third dose of BNT162b2 increased seventeen times that of 6 M after the second dose, and was twice higher than the peak antibody titers at 1 M after the second dose of vaccination. The negative effect of age for the male gender on anti-RBD IgG antibody titers was not observed at 1 M after the third dose of BNT162b2 vaccine. There were no notable adverse events reported, which required hospitalization in these participants. These results suggest that the third dose of BNT162b2 safely improves humoral immunity against SARS-CoV-2 with no major adverse events.